Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 2/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004394 | 0.86 | ENPP2 (0.42) | ENPP2 | |
| SCHEMBL4828522 | 0.86 | CHEK1 (0.40) | — | |
| SCHEMBL6003997 | 0.81 | HDAC3 (0.40) | ACKR3 | |
| SCHEMBL6004876 | 0.80 | TLR7 (0.44) | — | |
| SCHEMBL4762022 | 0.79 | TLR7 (0.43) | — | |
| SCHEMBL6004597 | 0.77 | TLR7 (0.42) | — | |
| SCHEMBL6003993 | 0.77 | TLR7 (0.39) | — | |
| SCHEMBL4721839 | 0.76 | MAPK11 (0.49) | ACKR3ENPP2 | |
| SCHEMBL4791362 | 0.76 | ACKR3 (0.41) | ACKR3ENPP2 | |
| SCHEMBL4915605 | 0.75 | MAPK14 (0.47) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ACKR3 262/4885TBK1 188/4885GRIA1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.